Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax added to anthracycline-free chemotherapy for relapsed pediatric and young adult AML
MOH_2022-10-25_012082Phase 3Recruiting
- Sponsor
- Princess Máxima Center for Pediatric Oncology
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of venetoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Princess Máxima Center for Pediatric Oncology. Started Sep 2022; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on MOH_2022-10-25_012082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-10-25_012082.